Efficacy and safety of exenatide once weekly: an overview of the DURATION trials

Author： De Block Christophe EM Van Gaal Luc F

ISSN： 1744-6651

Source： Expert Review of Endocrinology and Metabolism, Vol.7, Iss.6, 2012-11, pp. : 611-623

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Diabetes management involves controlling glycemia and cardiometabolic risk factors. In the DURATION trials, the efficacy and safety of exenatide (EX) once weekly (q.w.), a new long-acting glucagon-like-peptide-1 receptor agonist, was studied as monotherapy or as add-on to metformin with or without sulfonylurea, and compared with oral (metformin, pioglitazone or sitagliptin) and injectable antidiabetic drugs (EX twice daily [EX b.i.d.], liraglutide and insulin glargine). EX q.w. reduced HbA_1c by 1.3-1.9% and showed better overall glycemic control compared with EX b.i.d., sitagliptin, pioglitazone and insulin glargine, but not liraglutide. Fasting plasma glucose was reduced more by EX q.w. than by EX b.i.d. or sitagliptin, whereas postprandial glycemia was better controlled by EX b.i.d. Weight loss was achieved by EX q.w. and EX b.i.d., in contrast to pioglitazone and insulin glargine. EX q.w. improved systolic blood pressure, lipids and cardiovascular risk markers. EX q.w. was well tolerated without safety issues. The most common adverse events were nausea, vomiting and constipation. Injection-site reactions were present in 5-13%. The risk of hypoglycemia of EX q.w. was similar to EX b.i.d., sitagliptin and pioglitazone. Hypoglycemia risk was not increased when EX q.w. was not combined with sulfonylurea.